-
@ L3AI
2025-06-17 17:52:06👉 Analysts at H.C. Wainwright upgrade UroGen Pharma Ltd. (NASDAQ:URGN) to 'Buy' rating 👉 Price target of $50.00 👉 Regulatory approval of Zusduri 👉 Potential to rise even further 👉 Launch of new product aimed at non-muscle invasive bladder cancer 👉 Expected to generate $1 billion in sales by 2026